SBI Healthcare Opportunities Fund (Equity, Equity Sectoral-pharma)

20 yrs 10 monthsStarted on:05 Jul 1999
₹ 953.19 Cras on: 03 Apr 2020
Long Term Horizon
Capital Appreciation

Minimum Investment

  • ₹ 5000.00 for Lumpsum

Investment Objective

The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.

Exit Load

Scheme Documents

Similar Funds
Nippon India pharma fund
Current NAV 146.53
Return (CAGR) 18.47%
Value Research NA
TATA India Pharma & Health Care Fund
Current NAV 9.15
Return (CAGR) -2.06%
Value Research NA
UTI Healthcare Fund
Current NAV 81.86
Return (CAGR) 12.13%
Value Research NA


TenureReturns (CAGR)

SIP Returns

TenureReturns (CAGR)
1 YR1.12
10 YR7.52


Company Name% Assets
Divi's Laboratories Ltd.9.95
Sun Pharmaceutical Inds. Ltd.7.04
Abbott India Ltd.6.6
Lupin Ltd.6.58
Cipla Ltd.5.91
Torrent Pharmaceuticals Ltd.5.41
Alembic Pharmaceuticals Ltd.4.96
Strides Pharma Science Ltd.4.93
Ajanta Pharma Ltd.4.36
Alkem Laboratories Ltd.4.13

Top Sectoral Holdings

Sector Name% Assets


Portfolio turnover ratio61
Standard Deviation17.11%

Tanmaya Desai

Mr. Desai is a B.E. (Electronics), MBA (Finance) and CFA (Level III).
Prior to joining SBI Mutual Fund he has worked with D.J. Sanghvi College of Engineering and Patni Computer Systems Ltd.